MinervaX announces that the company has raised DKK 22 million (EUR 3 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment, and a Syndication Loan from The Danish Growth Foundation (VækstFonden).
MinervaX announces that the NeoStrep consortium, consisting of Lund University (Sweden), MinervaX ApS (Denmark), CiToxLAB A/S (Denmark), and BioKinetic Europe Ltd. (UK), has been awarded EUR 6 million in funding under the European Commission FP7 Programme HEALTH, for the development of a novel innovative Group B Streptococcal Vaccine candidate, owned by MinervaX.
MinervaX announces the award of a Eurostars Grant in collaboration with Bioneer (Denmark), The Danish Technical University (Denmark) and Telormedix (Switzerland) for the development of a LIPODEL adjuvant formulation of the NN GBS vaccine. Total grant budget amounts to 730,000 EUR.
MinervaX announces the award of a grant from The Danish National Advanced Technology Foundation together with The State Serum Institute and University of Copenhagen for the development and testing of a CAF Adjuvant formulation of the NN GBS vaccine as well as a Chlamydia vaccine candidate. The total grant budget amounts to 29.6 mDKK (3.9 mEUR).